SG10201606872TA - Anti-tie2 antibodies and uses thereof - Google Patents

Anti-tie2 antibodies and uses thereof

Info

Publication number
SG10201606872TA
SG10201606872TA SG10201606872TA SG10201606872TA SG10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA
Authority
SG
Singapore
Prior art keywords
tie2 antibodies
tie2
antibodies
Prior art date
Application number
SG10201606872TA
Inventor
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201606872TA publication Critical patent/SG10201606872TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201606872TA 2011-08-19 2012-08-16 Anti-tie2 antibodies and uses thereof SG10201606872TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23

Publications (1)

Publication Number Publication Date
SG10201606872TA true SG10201606872TA (en) 2016-10-28

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201606872TA SG10201606872TA (en) 2011-08-19 2012-08-16 Anti-tie2 antibodies and uses thereof

Country Status (15)

Country Link
US (4) US9017670B2 (en)
EP (2) EP3415533A1 (en)
JP (2) JP6333174B2 (en)
KR (1) KR20140054303A (en)
CN (2) CN106963946A (en)
AR (1) AR087567A1 (en)
AU (1) AU2012299195B9 (en)
CA (1) CA2844306C (en)
ES (1) ES2694411T3 (en)
IL (1) IL230529A (en)
IN (1) IN2014CN02025A (en)
MX (1) MX359833B (en)
SG (1) SG10201606872TA (en)
UY (1) UY34271A (en)
WO (1) WO2013028442A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017670B2 (en) 2011-08-19 2015-04-28 Regeneron Pharmaceuticals, Inc. Anti-Tie2 antibodies and uses thereof
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
HUE044660T2 (en) 2013-11-01 2019-11-28 Regeneron Pharma Angiopoietin-based interventions for treating cerebral malaria
EP3170841A4 (en) * 2014-07-15 2018-01-10 Astellas Pharma Inc. NOVEL ANTI-HUMAN Tie2 ANTIBODY
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
CN109071656B (en) 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
CA3052474A1 (en) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (en) 2018-02-20 2023-02-08 기초과학연구원 Anti-angiopoietin-2 Antibodies and Uses Thereof
AU2019283520A1 (en) * 2018-06-07 2021-01-07 Institute For Basic Science Antibody binding to Tie2 and use thereof
WO2019235856A1 (en) * 2018-06-07 2019-12-12 기초과학연구원 Antibody binding to tie2 and use thereof
EP3813864A4 (en) 2018-06-29 2022-07-20 Gensun Biopharma Inc. Antitumor antagonists
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
SG11202111656WA (en) * 2019-08-14 2021-11-29 Pharmabcine Inc Anti-tie2 antibody and use thereof
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology Antibodies directed to tie-2 and methods of use
EP4328242A1 (en) * 2021-04-23 2024-02-28 Neortesbio Inc. Antibody specifically binding to angiopoietin-2, or fragment thereof
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
WO2023137395A1 (en) * 2022-01-13 2023-07-20 Ingenia Therapeutics Inc. Vegf and tie2-binding fusion protein and uses thereof
CN115947818A (en) * 2022-10-25 2023-04-11 福州大学 Design of angiogenin 1 mutant and preparation method and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4651893A (en) 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
EP1187918B9 (en) * 1999-06-07 2009-08-19 Immunex Corporation Tek antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP2298334A3 (en) * 1999-12-20 2012-04-04 Immunex Corporation Tweak receptor
DE60128685T2 (en) 2000-06-23 2009-03-05 Bayer Schering Pharma Aktiengesellschaft COMPOSITIONS INTERFERING TO VEGF / VEGF AND ANGIOPOIETIN / TIE RECEPTOR FUNCTIONS
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006005361A1 (en) 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
JP2008532476A (en) * 2004-08-12 2008-08-21 ダイアックス コーポレーション Complex binding protein
WO2006112479A1 (en) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
PT2076290T (en) 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
US8685393B2 (en) * 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
US9017670B2 (en) 2011-08-19 2015-04-28 Regeneron Pharmaceuticals, Inc. Anti-Tie2 antibodies and uses thereof

Also Published As

Publication number Publication date
US10023641B2 (en) 2018-07-17
NZ621481A (en) 2016-04-29
UY34271A (en) 2013-02-28
ES2694411T3 (en) 2018-12-20
US20170088622A1 (en) 2017-03-30
IL230529A0 (en) 2014-03-31
US9546218B2 (en) 2017-01-17
CN103874709B (en) 2016-12-21
IL230529A (en) 2017-07-31
AU2012299195B2 (en) 2018-04-19
AR087567A1 (en) 2014-04-03
JP6333174B2 (en) 2018-05-30
AU2012299195A1 (en) 2014-03-13
US9017670B2 (en) 2015-04-28
WO2013028442A1 (en) 2013-02-28
US20180291105A1 (en) 2018-10-11
JP6654165B2 (en) 2020-02-26
EP2744827B1 (en) 2018-10-03
CN103874709A (en) 2014-06-18
US20150197578A1 (en) 2015-07-16
CA2844306A1 (en) 2013-02-28
MX359833B (en) 2018-10-12
EP2744827A1 (en) 2014-06-25
MX2014001738A (en) 2014-03-27
AU2012299195B9 (en) 2018-05-10
IN2014CN02025A (en) 2015-05-29
JP2017186347A (en) 2017-10-12
CA2844306C (en) 2022-08-16
CN106963946A (en) 2017-07-21
KR20140054303A (en) 2014-05-08
US10442864B2 (en) 2019-10-15
US20130209492A1 (en) 2013-08-15
EP3415533A1 (en) 2018-12-19
JP2014525934A (en) 2014-10-02

Similar Documents

Publication Publication Date Title
HUS2100034I1 (en) Anti-angptl3 antibodies and uses thereof
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
IL281250A (en) Anti-phf-tau antibodies and their uses
HUS2000056I1 (en) Anti-pd-l1 antibodies and uses thereof
IL230529A0 (en) Anti-tie2 antibodies and uses thereof
IL232399A0 (en) Anti-fgfr2 antibodies and uses thereof
EP2756094A4 (en) Anti-b7-h4 antibodies and their uses
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15